Client Alerts & Insights
Private Equity: Do You Have Seats on Boards of Companies in the Same Industry?
September 28, 2022
Authored By:
Last week, the U.S. Department of Justice (DOJ) sent letters to multiple public companies, investors and individuals advising of concerns of “interlocking directorates” and stating that it may bring lawsuits for violations of Section 8 of the Clayton Antitrust Act (15 U.S.C. § 19) (Section 8). Section 8 prohibits “interlocking directorates.” An “interlocking directorate” occurs when the same individual or entity sits on the board of two competitors. Direct interlocking directorates are easy to identify and occur when the same individual sits on the board of two competing companies within the same industry. Indirect interlocking directorates occur when the same entity appoints two different individuals to sit on the board of two competing companies.
Many private equity firms target investments in companies within a particular industry. They are able to build on an understanding of a particular industry and relationships with key individuals. These industry ties are sought in merger filings made pursuant to the Hart Scott Rodino Act of 1976 (the HSR Act) as part of the affiliate and associate overlap analysis.
Traditionally, the DOJ and Federal Trade Commission (FTC) have enforced Section 8 prohibitions in the context of HSR Act filings. Last week’s actions by the DOJ were the result of proactive searches for violations of Section 8 prohibitions outside the merger review context and indicate the DOJ is expanding its efforts to identify and take actions against interlocking directorates. The goal of these prohibitions is to ensure that competitively sensitive information (such as pricing, key suppliers, key customers and key employees) is not being shared among competitors resulting in anticompetitive effects through coordination of competitive activities within a given industry.
Parties are strictly liable for Section 8 violations. The DOJ does not have to prove actual competitive harm resulting from an interlocking directorate. The remedy is injunctive relief, but if a private plaintiff builds on a finding, private plaintiffs may obtain monetary damages for Section 8 violations. There are “safe harbor” exceptions if (1) the corporation has less than $41,034,000 in total capital, surplus, and undivided profits or (2) (a) the competitive sales of either corporation are less than $4,103,400, (b) the competitive sales of either corporation are less than two percent of the corporation’s total sales or (c) the competitive sales of each corporation are less than four percent of the corporation’s total sales.
If you have further questions about this target of enforcement or to review your compliance with Section 8, please contact the following attorneys from Benesch’s Corporate and Securities Practice Group:
Connie Porter, Partner at 216.363.4433 or cporter@beneschlaw.com
Anthony Rossi, Associate at 216.363.6242 or arossi@beneschlaw.com
Logan Bryant, Associate at 216.363.6217 or lbryant@beneschlaw.com
Latest News
Medical First, Recreational Later? DOJ’s Cannabis Order and the Stakes Ahead
DOJ’s April 2026 order immediately moved FDA-approved and state-licensed medical cannabis to Schedule III, removing harsh tax penalties for medical operators, while leaving adult-use cannabis under stricter Schedule I controls pending further administrative review.
New Sentencing Guidelines for Economic Crimes Effective November 1, 2026
In March we reported on the U.S. Sentencing Commission’s proposed amendments to the Federal Sentencing Guidelines (the “Guidelines”). On April 16, 2026, the bipartisan United States Sentencing Commission (the “Commission”) voted unanimously to adopt that package of amendments, without modification.
Judicial Green Light: Court Upholds NLRB’s Cemex Decision
On April 21st, 2026, the U.S. Court of Appeals for the Ninth Circuit upheld the National Labor Relations Board’s (“NLRB”) decision in Cemex Construction Materials Pacific, LLC., reinforcing a significant shift in federal labor law governing union recognition and employer conduct during organizing campaigns.
The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here
The new LEAD Model, launching in 2027, is CMS’s next-generation value-based care framework for kidney care, integrating CKD and ESRD patients into standard ACOs with a 10-year benchmark period, new payment options and greater flexibility for nephrology-led organizations.